A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 617 participants.
Also called NCT05079919
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 617 participants
- Sponsor
- Registry
-
NCT05079919 -
2021-002192-19 -
2024-510696-38-00
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Australia, Bulgaria, Canada, Czechia, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Netherlands, New Zealand, Norway, Poland, Portugal, Slovakia, South Africa, Spain, Sweden, Türkiye, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT05079919. Randomized; triple masking; primary purpose treatment. Start 2021-10-25 (actual); primary completion 2024-10-22 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia
- Condition
- Severe Hypertriglyceridemia
- Intervention (Drug)
- Olezarsen
- Intervention (Drug)
- Placebo
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
Record details
- Record id
cardio:ct-nct05079919- Content hash
59cbdf3bea98d1ecb27d9b30ef0f8dca47af8bc559e552d7680edd1af180d207